Black Titan Corp (NASDAQ:BTTC – Get Free Report) dropped 1% during mid-day trading on Friday . The stock traded as low as $1.8007 and last traded at $1.89. Approximately 76,354 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 3,903,502 shares. The stock had previously closed at $1.91.
Analysts Set New Price Targets
Separately, Weiss Ratings assumed coverage on Black Titan in a report on Monday, January 26th. They issued a “sell (e-)” rating on the stock. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Black Titan has an average rating of “Sell”.
View Our Latest Analysis on Black Titan
Black Titan Stock Performance
About Black Titan
Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.
Featured Articles
- Five stocks we like better than Black Titan
- Stock market legend warns: “An Ominous Day Is Coming for the Markets…”
- Another reason you need to own gold… [running out]
- Trump’s Final Shocking Act Begins February 24
- NEW: Gold makes history
- Deutsche Bank Just Raised Their Gold Target to $6,000
Receive News & Ratings for Black Titan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Titan and related companies with MarketBeat.com's FREE daily email newsletter.
